News

The milestone was reached on the transition of an oncology programme into lead optimisation. The collaboration was made for jointly indentifying and developing preclinical development candidates for the

MEDI-565 (MT111) is a BiTE antibody designed to direct a patient’s T cells, the body’s most potent killer cells, against cancer cells that express carcinoembryonic antigen (CEA). The

The collaboration will enable more patients to participate in trials of potential new cancer treatments that combine molecularly targeted experimental drugs developed and owned by AstraZeneca. The trials

GSK and ChemoCentryx said that the study will assess the efficacy and safety of ‘786 for inducing a response and remission (reduction or disappearance of symptoms) and maintaining

Under the agreement DSM Pharmaceutical can use Codexis’ custom biocatalysts and services, and secures supply of Codexis enzymes for commercialization of sustainable enzyme-based pharmaceutical manufacturing routes developed by

GloStream said doctors can use gloEMR to improve efficiency, productivity, and compliance with meaningful use criteria, which they must prove to collect Stimulus incentive funding. gloStream chief information

According to data compiled by Bloomberg, Endo Pharmaceuticals has completed six deals in the past five years, with an average size of $352.8m and a typical premium of

Caliper Life Sciences president and CEO Kevin Hrusovsky said the deal will improve the economics of diagnostic testing and advance the worldwide implementation of personalised medicine. "We believe

The GeneAtlas System is the first personal microarray system, designed to meet the demand for an easy to use and affordable way to interrogate the whole genome. The